Table 1.

Ongoing clinical trials for Hydroxychloroquine on COVID-19.

Name	Identifier	Location	Type of study What to measure	Treatment arm	Active comparator	Placebo arm
Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)	NCT04307693	Sung-Han Kim, Asan Medical Center, Seoul, South Korea	Multicentre, open-labelled, randomised clinical trial Viral load	Lopinavir/ritonavir 200 mg/100 mg two tablets by mouth, every 12 hours for 7–10 days	Hydroxychloroquine 200 mg two tablets by mouth, every 12 hours for 7–10 days	No lopinavir/ritonavir and hydroxychloroquine
Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)	NCT04318444	Elizabeth Oelsner, Columbia University, NY, USA	Parallel assignment (randomised)	Hydroxychloroquine two tablets (400 mg) twice daily on day 1; for days 2–5, they will be instructed to take one tablet (200 mg) twice daily		Two tablets (400 mg) twice daily on day 1; for days 2–5, they will be instructed to take one tablet (200 mg) twice daily
Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial) (PHYDRA	NCT04318015	National Institute of Respiratory Diseases, Mexico City, Mexico	Triple blinded, randomised controlled trial Symptomatic covid-19 infection rate	High risk: hydroxychloroquine 200 mg per day for 60 days Low risk: hydroxychloroquine 200 mg per day for 60 days		High risk: placebo tablet per day for 60 days Low risk: placebo tablet per day for 60 days
Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV)	NCT04303507	Oxford University, Oxford, UK	Parallel assignment Number of symptomatic covid-19 infections	Chloroquine A loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months		Placebo
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS CoV-2 Virus (Alliance COVID-19 Brasil II)	NCT04321278	Hospital Israelita Albert Einstein, Sao Paulo, Brazil	Parallel assignment Evaluation of clinical status	Hydroxychloroquine (400 mg 2 times per day, 12/12 hours)+azithromycin (500 mg once a day)	Hydroxychloroquine (400 mg 2 times per day, 12/12 hours)
Post-exposure Prophylaxis for SARS-Coronavirus-2	NCT04308668	University of Minnesota, Minnesota, USA	Parallel assignment Incidence of disease	Hydroxychloroquine 200 mg tablet; 800 mg orally once, followed in 6–8 hours by 600 mg, then 600 mg once a day for four consecutive days		Placebo four placebo tablets once, followed in 6–8 hours by three tablets, then three tablets once a day for four consecutive days